The future of small molecule inhibitors in lymphoma.
For the many patients with lymphoma that has relapsed after and/or has become refractory to existing treatments, the development of novel therapeutics is imperative. Investigation into intracellular processes that are dysregulated during lymphomagenesis has uncovered several new potential targets for anticancer agents. Although monoclonal antibodies and other immunotherapeutics have led to dramatic advances in the treatment of patients with lymphoma, the parallel development of small molecule inhibitors has been equally exciting. These agents, whose small size allows direct entry into tumor cells, can target distinct proteins or complexes, thereby disrupting molecular processes on which neoplastic cells depend for survival and growth. This review surveys the published literature on many of these new targeted molecules, focusing on some of the most promising agents for which phase 2 data currently exist. It also explores the potential for incorporating these agents into broader multidrug regimens.
Gerecitano
John
J
Department of Medicine, Lymphoma Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA. gerecitj@mskcc.org
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D055808:Drug Discovery / Q000639:trends; D005544:Forecasting; D006655:Histone Deacetylases; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy* / Q000473:pathology; D009842:Oligopeptides / Q000627:therapeutic use; D011480:Protease Inhibitors / Q000627:therapeutic use*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000037:antagonists & inhibitors; D011719:Pyrazines / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001897:Boronic Acids; D009842:Oligopeptides; D011480:Protease Inhibitors; D019253:Proto-Oncogene Proteins c-bcl-2; D011719:Pyrazines; D000069286:Bortezomib; C524865:carfilzomib; D006655:Histone Deacetylases
Curr Opin Drug Discov Devel. 2005 Jul;8(4):431-6
16022179
Blood. 2008 Feb 15;111(4):2230-7
18006696
Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19512-7
18040043
Clin Cancer Res. 2006 Sep 1;12(17):5165-73
16951235
Curr Opin Oncol. 2003 Nov;15(6):419-24
14624223
J Clin Oncol. 2005 Feb 1;23(4):676-84
15613699
J Clin Oncol. 2005 Oct 20;23(30):7697-702
16186597
Clin Cancer Res. 2008 Jul 15;14(14):4500-10
18628465
Leuk Lymphoma. 2007 Jul;48(7):1313-9
17613759
Ann Oncol. 2007 Jan;18(1):116-121
16971665
J Clin Oncol. 2007 Mar 20;25(9):1114-20
17296974
J Clin Oncol. 2007 Jul 20;25(21):3109-15
17577020
Oncologist. 2007 Jun;12(6):664-89
17602058
Br J Haematol. 2009 Sep;146(6):652-5
19624539
J Clin Oncol. 2006 Jan 1;24(1):166-73
16330674
Expert Opin Investig Drugs. 2008 Jun;17(6):879-95
18491989
Blood. 2009 Feb 19;113(8):1723-9
19064730
Blood. 2009 May 7;113(19):4667-76
19050304
Br J Haematol. 2010 Oct;151(1):47-53
20735402
Cancer Res. 2007 Jul 1;67(13):6383-91
17616698
J Clin Oncol. 2005 Aug 10;23(23):5347-56
15983389
Blood. 2008 Apr 1;111(7):3322-30
18362212
Nature. 2009 Apr 9;458(7239):732-6
19360080
Oncologist. 2006 Jan;11(1):51-61
16401713
J Clin Oncol. 2002 Nov 15;20(22):4420-7
12431963
J Clin Oncol. 2000 May;18(9):1812-23
10784621
Br J Cancer. 2006 Oct 23;95(8):961-5
17047643
Expert Rev Mol Med. 2008 Feb 04;10:e4
18241520
J Clin Oncol. 2005 Feb 1;23(4):667-75
15613697
Blood. 2009 Apr 2;113(14):3154-60
19096013
Blood. 2007 Jan 1;109(1):31-9
16960145
Nat Rev Cancer. 2008 Feb;8(2):121-32
18202696
Ann Oncol. 2009 Mar;20(3):520-5
19074748
Blood. 2009 Jan 8;113(2):299-305
18931344
Expert Rev Anticancer Ther. 2006 Jan;6(1):109-20
16375648
Expert Rev Anticancer Ther. 2008 Mar;8(3):413-32
18366289